Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02073682 · ClinicalTrials.gov registry record · Phase 3

Cancer Venous Thromboembolism (VTE)

A Phase 3 study of Cancer and Deep Vein Thrombosis (DVT), sponsored by Daiichi Sankyo.

Completed
Registry status
Phase 3
Development phase
1,046
Enrollment target
9
Study locations

NCT02073682 is a Phase 3 study of Cancer and Deep Vein Thrombosis (DVT) that has completed, run by Daiichi Sankyo. The registered enrollment target is 1,046 participants, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (70% lower). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02073682, a Phase 3 study of Cancer and Deep Vein Thrombosis (DVT), has completed, sponsored by Daiichi Sankyo.

COMPLETED
Registry status
Phase 3
Development phase
1,046 participants
Enrollment target
9
Study locations

Study Summary

The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major bleeding in subjects with VTE associated with cancer during a 12-month study period. If non-inferiority is established, LMWH/edoxaban will be compared with dalteparin for superiority.

Conditions Studied

Cancer Deep Vein Thrombosis (DVT) Venous Thromboembolism (VTE) Pulmonary Embolism (PE)

Interventions

  • DRUG Edoxaban
  • DRUG Dalteparin
  • DRUG Low molecular weight heparin

Study Locations (9)

Other

  • - Saint-Etienne
  • - Varese
  • - Amsterdam

Florida

  • - Brandon

Georgia

  • - Jonesboro

Michigan

  • - Detroit

Virginia

  • - Norfolk

Vlaams-Brabant

  • - Leuven

Hajdu-Bihar Megye

  • - Debrecen

Trial Details

FieldValue
Enrollment Target 1,046 participants
Start Date 2015-07-16
Est. Completion 2017-09-15
Phase Phase 3

Sponsor

Daiichi Sankyo

236 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02073682

The ClinicalTrials.gov registry entry for NCT02073682 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,046 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (70% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 3 interventions - of which Edoxaban is the first listed.

NCT02073682 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Other, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT02073682 about?

NCT02073682 is a clinical study titled "Cancer Venous Thromboembolism (VTE)". The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major bleeding in subjects with VTE associated with cancer during a 12-month s...

What is the current status of trial NCT02073682?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,046 participants. The study started on 2015-07-16. Estimated completion is 2017-09-15.

What conditions does trial NCT02073682 study?

This clinical trial studies the following conditions: Cancer, Deep Vein Thrombosis (DVT), Venous Thromboembolism (VTE), Pulmonary Embolism (PE).

What interventions are being tested in trial NCT02073682?

The interventions under investigation include: Edoxaban (DRUG), Dalteparin (DRUG), Low molecular weight heparin (DRUG).

Who is sponsoring clinical trial NCT02073682?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02073682 being conducted?

This trial has 9 study locations across Florida, Georgia, Michigan, Virginia, Vlaams-Brabant. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

Deep Vein Thrombosis (DVT)

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.